Not So Different: The Fight to Align Payer Preferences With Community Oncology

This is the third and final part of our series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.

In March 2021, the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program, in partnership with Pfizer, announced 10 research projects that will receive funding to develop innovative ways to improve biosimilar adoption in the oncology space.

For this Not So Different series, The Center for Biosimilars® is spotlighting 3 projects to improve perception of biosimilars, promote biosimilars as a therapy choice, and encourage payers to prefer biosimilar use.

In this third part, we spoke with Hong-Phuc Nguyen, PharmD, director of the pharmacy clinical network at City of Hope in Duarte, California. Dr Nguyen discussed how his project titled “Challenges to Biosimilar Adoption in Community Oncology Due to Diverse Payer Preferences for Different Biosimilars” will address how payer formulary decisions can improve or stall biosimilar uptake and acceptance.

To learn more about payer preferences, click here.

To see how Minnesota legislators are working to override payer preferences, click here.

For more on payer influence on prescribing patterns, click here.

For more on NCCN’s biosimilar work, click here.

You can also check out part 1 and part 2 of this series.

To check out our Biosimilar Approvals navigator, click here.